AUS
NZ
UK
CA
USA
IND
_06_19_2026_12_34_15_139937.jpg)
Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company specializing in novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, has announced significant leadership changes aimed at enhancing its operational success and advancing its clinical programs. Effective September 18, Blai Coll, M.D., Ph.D., has been promoted to Chief Medical Officer, succeeding Mark Bach, M.D., Ph.D., as part of a planned succession strategy.
Dr. Coll, who previously served as Vice President of Clinical Development at Structure, has been instrumental in leading the GSBR-1290 program. This oral small molecule GLP-1 agonist is poised to enter Phase 2b clinical development for obesity in the fourth quarter of 2024. His extensive experience in the cardiometabolic clinical space positions him well to guide the company’s next phase of development.
In addition, Ashley Hall, J.D., has been appointed to the newly created role of Chief Development Officer. Hall will oversee clinical development operations, project management, regulatory affairs, and quality assurance, leveraging her robust background in global clinical development.
Raymond Stevens, Ph.D., Founder and CEO of Structure Therapeutics, expressed enthusiasm about the expanded clinical leadership team. “Our strengthened leadership enhances our capability to execute efficiently as we transition into Phase 2b development of GSBR-1290,” Stevens stated. He emphasized the importance of Hall’s expertise in regulatory strategy and clinical operations for accelerating the development of their oral small molecules targeting cardiometabolic diseases. Stevens also acknowledged Dr. Bach’s contributions to establishing the clinical organization, thanking him for his leadership during the transition.
About Blai Coll, M.D., Ph.D.
Dr. Coll is a seasoned physician-scientist with 15 years of experience in clinical development. Before his promotion, he led clinical activities for GSBR-1290 as Vice President of Endocrine and Metabolism Clinical Development at Structure. His previous roles include significant positions at Amgen, where he managed lifecycle studies for Repatha® and led early development projects in the cardiovascular domain. He also served as Medical Director at AbbVie, overseeing late-stage clinical programs for chronic kidney disease.
About Ashley Hall, J.D.
Ms. Hall brings over 23 years of experience in global clinical development operations and regulatory affairs. She has been involved in the development of therapies such as Repatha®, Nexletol®, and Nexlizet®, all crucial for managing hyperlipidemia and reducing cardiovascular risk. Before joining Structure Therapeutics, Hall was Chief Development Officer at Reneo Pharmaceuticals and previously held similar roles at Esperion Therapeutics, where she directed pivotal trials for LDL-C lowering therapies.
These leadership appointments position Structure Therapeutics to further its mission in developing innovative therapies for metabolic and cardiopulmonary diseases, enhancing the company’s trajectory in the biopharmaceutical landscape.
